Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vanguard Total International Stock Index Fund ETF trades at $83.12 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 177.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 4,659,186). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Total International Stock Index Fund ETF for 56 Days on average.
| TNGX | VXUS | |
|---|---|---|
Market Cap | $3.75B | $665.70B |
Volume | 9,619,106 | 4,659,186 |
Sector | Health | Sector/Thematic |
52-Week High | $32.90 | $88.41 |
52-Week Low | $7.50 | $72.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VXUS trades at $84.54 with minimal daily movement (+0.12%). Technical indicators show bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF provides broad international stock exposure outside the U.S., offering diversification benefits. Recent institutional activity shows growing interest, with firms like QRG Capital increasing positions by 97.8% in Q2 2026 (SEC filing, September 2026).
VXUS offers cost-effective international diversification but faces currency and geopolitical risks. Current bearish technicals suggest near-term pressure, while long-term prospects depend on global market performance versus U.S. equities. The upcoming $0.16 dividend in September 2026 provides income, but foreign tax credit limitations in IRAs may reduce net returns for some investors (24/7 Wall Street, August 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
